… by demand for its new cystic fibrosis drug and product launches. Revenue … trial. Vertex, a leader in cystic fibrosis drugs, has been diversifying into … to expand its global reach. Cystic fibrosis is a genetic disorder caused …

… General Hospital’s paediatric Cystic Fibrosis unit. At the beginning … Eastbourne DGH Scott unit Cystic Fibrosis clinic received a donation … Eastbourne DGH Scott unit Cystic Fibrosis clinic received a donation … 41 Club to the Cystic Fibrosis Clinic. Seeing the …

… serial innovation had generated their (cystic fibrosis) leadership," RBC Capital Markets … .27. Vertex credited Journavx, new cystic fibrosis treatment Alyftrek and Casgevy, a …

… 2020 purchase of Vertex Pharmaceuticals’ cystic fibrosis royalties (2). For drug manufacturers … Additional Royalty Interest from the Cystic Fibrosis Foundation. Press Release. Nov. 2 …

… launch of its most important cystic fibrosis medicine, Trikafta, alongside the development …

… Psychosis Haemophilia Blood Disorders Asthma Cystic Fibrosis Personality Disorder Diabetes Mellitus Chronic …

… Psychosis Arthritis Deaf/Blind Cystic Fibrosis Spondylosis Psychoneurosis Respiratory Disorders and …

… Business Highlights Marketed Products Cystic Fibrosis (CF) Portfolio Vertex has … another responsive mutation in the cystic fibrosis transmembrane conductance regulator (CFTR … life-shortening genetic diseases — cystic fibrosis, sickle cell disease and …

… by the continued performance of cystic fibrosis (CF) therapies and early contributions … focused on expanding leadership in cystic fibrosis, executing the launches, advancing the …

… such as sickle cell disease, cystic fibrosis, and rare conditions like Rett …